Adagio Medical Holdings (ADGM) Research & Development (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Research & Development fell 25.09% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 13.28% YoY) and the FY2025 annual result came in at $10.6 million, up 129.59% from the prior year.
• Research & Development grew to $2.7 million in Q1 2026 per ADGM's latest filing, from $2.2 million in the prior quarter.
• Across five years, Research & Development topped out at $4.4 million in Q3 2023 and bottomed at $1.2 million in Q3 2024.
• The 4-year median for Research & Development is $2.8 million (2025), against an average of $2.7 million.
• The widest annual swing landed in 2024, when Research & Development tumbled 72.45%; it then jumped 127.94% in 2025.
• Tracing ADGM's Research & Development over 4 years: stood at $1.8 million in 2023, then tumbled by 31.4% to $1.2 million in 2024, then jumped by 83.65% to $2.2 million in 2025, then increased by 22.64% to $2.7 million in 2026.
• Per Business Quant, the three latest ADGM Research & Development figures stand at $2.7 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025).

Peer Comparison